Adaptive Biotechnologies Corporation - Common Stock (ADPT)

Adaptive Biotechnologies (NASDAQ:ADPT) reported third-quarter net income and raised its full-year revenue outlook for its minimal residual disease business, as demand for its clonoSEQ cancer testing service increased in both clinical care and drug development. The company reported total revenue of

Adaptive Biotechnologies (NASDAQ:ADPT) reported second-quarter results marked by accelerating growth in its minimal residual disease, or MRD, business, improved margins and an increased full-year revenue outlook. The company also outlined further steps toward separating its Immune Medicine operation

Harlan Robins liquidated 386,240 shares under a pre-scheduled Rule 10b5-1 trading plan, retaining over 1 million shares worth $21.6 million.

Adaptive Biotechnologies, a leader in immune-driven diagnostics, reported a notable insider sale amid strong year-over-year share gains.

Adaptive Biotechnologies (NASDAQ:ADPT) Chief Executive Officer and Co-Founder Chad Robins said the company is focused on expanding its minimal residual disease testing business while pursuing targeted partnerships for its Immune Medicine platform, during a presentation at William Blair’s Growth Stoc

Adaptive Biotechnologies develops immune-driven diagnostics and research tools for the life sciences and healthcare sectors.

Adaptive (ADPT) Q1 2026 Earnings Transcript

This immune diagnostics innovator reported a notable insider sale as it advances platforms for disease detection and monitoring.

This immune diagnostics firm reported a notable insider sale as it expands its clinical portfolio and strategic partnerships.

This Seattle-based biotech, known for its immune medicine platform, reported a notable insider sale amid ongoing industry partnerships.

This immuno-driven diagnostics company, known for partnerships with Genentech and Microsoft, just reported a notable insider sale.

Adaptive Biotechnologies, a leader in immune-driven diagnostics, reported a notable insider sale amid strong one-year stock gains.

Adaptive Biotechnologies, a leader in immune-driven diagnostics, saw a notable insider sale amid ongoing innovation in disease monitoring.

Adaptive Biotechnologies, a leader in immune-driven diagnostics, reported a notable insider sale after a strong one-year stock performance.

Adaptive Biotech (ADPT) Earnings Call Transcript

Shares of Adaptive Biotechnologies (NASDAQ: ADPT) soared on Tuesday, January 13, 2026, after the life sciences company announced preliminary fourth-quarter and full-year 2025 financial results that blew past Wall Street expectations. The report highlighted a dramatic acceleration in the adoption of its clonoSEQ diagnostic test, positioning the company as a

As the final trading days of 2025 wind down, the biotechnology sector finds itself caught in a paradoxical "bifurcated" squeeze. While the broader indices have touched record highs this year, a sharp wave of year-end tax-loss harvesting has sent many mid-cap and commercial-stage biotech firms into a tailspin. Investors, eager

Cathie Wood-led Ark Invest purchased shares in Bullish, a crypto exchange backed by Peter Thiel, through three of its funds. Other key trades were also made, including buying shares in CRISPR and Beam Therapeutics.